Log In
BCIQ
Print this Print this
 

XAF5

  Manage Alerts
Collapse Summary General Information
Company Allergan plc
DescriptionProstaglandin analog that induces a G protein-coupled cascade in adipocytes to reduce cellular lipid content and differentiation
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationBody Fat
Indication DetailsReduce excess eyelid fat (steatoblepharon); Reduce submental (under chin) fat
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$85.0M

$85.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

04/21/2016

$85.0M

$85.0M

Undisclosed

Get a free BioCentury trial today